Skip to content

Host Response and Pathogen Genomics in Childhood Respiratory Infection

Observational Study Integrating Host Response Biomarkers With Pathogen Genomics for Precision Diagnosis in Children With Severe Respiratory Infection

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07545096
Acronym
INTERACT
Enrollment
50
Registered
2026-04-22
Start date
2026-05-01
Completion date
2027-03-01
Last updated
2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Brief summary

A major challenge in children's infections is that it is difficult to work out which bug is making them unwell. Tests can find the bugs that are present though there can be more than one. Some bugs may just be bystanders and not actually making the child sick. Children still receive antibiotics because it is not always clear that they don't need them. This project explores whether measuring how the body is reacting to the bugs gives precise information about which bug is actually making them sick. It will investigate children in intensive care who are suspected of having a chest infection. This study uses a novel technology called "metagenomics" to detect any bacteria or viruses in the lung. Alongside this, investigators will measure how the lungs respond to the bugs through further tests of cells and proteins collected from the lung fluid. This fluid will be tested to see if the response is due to bacteria or viruses. Collecting lung fluid samples requires that children are sedated and intubated, having a breathing tube in place. This means that only children intubated in intensive care are eligible. Extra samples of lung fluid and blood will be collected when being taken for routine clinical care. If these tests work, they have the potential to give rapid and accurate information about what type of infection is taking place in the lung. This means the correct antibiotics can be given to children who need them and avoid the harms of giving them to children who do not. This can reduce cost, improve patient outcomes and help limit the development of antibiotic resistance.

Interventions

OTHERNon-Interventional Study

No intervention

Sponsors

Guy's and St Thomas' NHS Foundation Trust
Lead SponsorOTHER
King's College London
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 16 Years
Healthy volunteers
No

Inclusion criteria

* Admission to PICU and intubated and ventilated (including via tracheostomy) * Possible or proven lower respiratory tract infection

Exclusion criteria

* Imminent death or palliative care pathway planned

Design outcomes

Primary

MeasureTime frame
Protein biomarker in the bronchoalveolar lavage fluidDay 1
Host transcriptome detectable in bronchoalveolar fluidDay 1
Cellular host response in bronchoalveolar fluidDay 1

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026